A mismatch between β-oxidation and the tricarboxylic acid cycle (TCA) cycle flux in mitochondria produces an accumulation of
lipid metabolic intermediates, resulting in both blunted metabolic flexibility and decreased
glucose utilization in the affected cells. The ability of the cell to switch to
glucose as an energy substrate can be restored by reducing the reliance of the cell on
fatty acid oxidation. The inhibition of the
carnitine system, limiting the
carnitine shuttle to the oxidation of
lipids in the mitochondria, allows cells to develop a high plasticity to metabolic rewiring with a decrease in
fatty acid oxidation and a parallel increase in
glucose oxidation. We found that
3-(2,2,2-trimethylhydrazine)propionate (THP), which is able to reduce cellular
carnitine levels by blocking both
carnitine biosynthesis and the cell membrane
carnitine/
organic cation transporter (OCTN2), was reported to improve
mitochondrial dysfunction in several diseases, such as
Huntington's disease (HD). Here, new THP-derived
carnitine-lowering agents (TCL), characterized by a high affinity for the OCTN2 with a minimal effect on
carnitine synthesis, were developed, and their
biological activities were evaluated in both in vitro and in vivo HD models. Certain compounds showed promising
biological activities: reducing
protein aggregates in HD cells, ameliorating motility defects, and increasing the lifespan of HD Drosophila melanogaster.